Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
暂无分享,去创建一个
Richard J. Lee | A. Lazar | Michelle D. Williams | Kevin B. Kim | K. Nolop | Richard J Lee | S. Sherman | M. Cabanillas | Alexander J. Lazar | Keith Nolop | Maria E. Cabanillas | Deborah L. Sanders | Joseph L. Ilagan | Steven I. Sherman | D. Sanders | J. L. Ilagan | M. Williams
[1] P. Miccoli,et al. Dedifferentiated thyroid cancer: a therapeutic challenge. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[2] G. Schwartz,et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Fagin,et al. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. , 2006, Endocrinology.
[4] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[5] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Jiachao Liang,et al. Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Schlumberger,et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[9] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[10] Guojun Wu,et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. , 2005, The Journal of clinical endocrinology and metabolism.
[11] Mariana Brait,et al. Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] B. Goh,et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. , 2010, The Lancet. Oncology.
[13] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[14] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[15] H. Jeon,et al. Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[16] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[17] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[18] M. Xing,et al. Prognostic utility of BRAF mutation in papillary thyroid cancer , 2010, Molecular and Cellular Endocrinology.
[19] J. Olson,et al. Thyroid carcinoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] M. Santoro,et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.
[21] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[22] Michelle D. Williams,et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. , 2010, The Journal of clinical endocrinology and metabolism.
[23] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[24] S. Diaz-Cano. Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.
[25] P. Ladenson,et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Sherman. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. , 2009, The Journal of clinical endocrinology and metabolism.
[27] J. Shah,et al. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. , 1996, American journal of surgery.
[28] M. Santoro,et al. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. , 2009, The Journal of clinical endocrinology and metabolism.
[29] S. Sherman. Cytotoxic chemotherapy for differentiated thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[30] B. Trink,et al. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). , 2011, Biochemical and biophysical research communications.
[31] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[32] A. El‐Naggar,et al. High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma , 2009, Clinical Cancer Research.
[33] A. Pinchera,et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.
[34] A. Hauschild,et al. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Andrea B Troxel,et al. Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S. Filetti,et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. , 2007, The Journal of clinical endocrinology and metabolism.
[37] E. Vokes,et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] M. Ladanyi,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] J. Desai,et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. , 2010 .
[40] C. Robert,et al. RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.